Literature DB >> 26753066

Combined value of apparent diffusion coefficient-standardized uptake value max in evaluation of post-treated locally advanced rectal cancer.

Davide Ippolito1, Davide Fior1, Chiara Trattenero1, Elena De Ponti1, Silvia Drago1, Luca Guerra1, Cammillo Talei Franzesi1, Sandro Sironi1.   

Abstract

AIM: To assess the clinical diagnostic value of functional imaging, combining quantitative parameters of apparent diffusion coefficient (ADC) and standardized uptake value (SUV)max, before and after chemo-radiation therapy, in prediction of tumor response of patients with rectal cancer, related to tumor regression grade at histology.
METHODS: A total of 31 patients with biopsy proven diagnosis of rectal carcinoma were enrolled in our study. All patients underwent a whole body (18)FDG positron emission tomography (PET)/computed tomography (CT) scan and a pelvic magnetic resonance (MR) examination including diffusion weighted (DW) imaging for staging (PET1, RM1) and after completion (6.6 wk) of neoadjuvant treatment (PET2, RM2). Subsequently all patients underwent total mesorectal excision and the histological results were compared with imaging findings. The MR scanning, performed on 1.5 T magnet (Philips, Achieva), included T2-weighted multiplanar imaging and in addition DW images with b-value of 0 and 1000 mm²/s. On PET/CT the SUVmax of the rectal lesion were calculated in PET1 and PET2. The percentage decrease of SUVmax (ΔSUV) and ADC (ΔADC) values from baseline to presurgical scan were assessed and correlated with pathologic response classified as tumor regression grade (Mandard's criteria; TRG1 = complete regression, TRG5 = no regression).
RESULTS: After completion of therapy, all the patients were submitted to surgery. According to the Mandard's criteria, 22 tumors showed complete (TRG1) or subtotal regression (TRG2) and were classified as responders; 9 tumors were classified as non responders (TRG3, 4 and 5). Considering all patients the mean values of SUVmax in PET 1 was higher than the mean value of SUVmax in PET 2 (P < 0.001), whereas the mean ADC values was lower in RM1 than RM2 (P < 0.001), with a ΔSUV and ΔADC respectively of 60.2% and 66.8%. The best predictors for TRG response were SUV2 (threshold of 4.4) and ADC2 (1.29 × 10(-3) mm(2)/s) with high sensitivity and specificity. Combining in a single analysis both the obtained median value, the positive predictive value, in predicting the different group category response in related to TRG system, presented R(2) of 0.95.
CONCLUSION: The functional imaging combining ADC and SUVmax in a single analysis permits to detect changes in cellular tissue structures useful for the assessment of tumour response after the neoadjuvant therapy in rectal cancer, increasing the sensitivity in correct depiction of treatment response than either method alone.

Entities:  

Keywords:  Advanced rectal cancer; Apparent diffusion coefficient; FDG-PET/CT; Functional imaging; Magnetic resonance imaging; Neoadjuvant treatment; Tumor regression grade

Year:  2015        PMID: 26753066      PMCID: PMC4697125          DOI: 10.4329/wjr.v7.i12.509

Source DB:  PubMed          Journal:  World J Radiol        ISSN: 1949-8470


  45 in total

1.  Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer.

Authors:  Seung Ho Kim; Jae Young Lee; Jeong Min Lee; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2010-10-27       Impact factor: 5.315

2.  Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy--conventional MR volumetry versus diffusion-weighted MR imaging.

Authors:  Luís Curvo-Semedo; Doenja M J Lambregts; Monique Maas; Thomas Thywissen; Rana T Mehsen; Guido Lammering; Geerard L Beets; Filipe Caseiro-Alves; Regina G H Beets-Tan
Journal:  Radiology       Date:  2011-06-14       Impact factor: 11.105

3.  Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.

Authors:  Skandan Shanmugan; Rodrigo Arrangoiz; James R Nitzkorski; Jian Q Yu; Tianyu Li; Harry Cooper; Andre Konski; Jeffrey M Farma; Elin R Sigurdson
Journal:  Ann Surg Oncol       Date:  2012-03-07       Impact factor: 5.344

4.  18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer.

Authors:  Giuseppe Lucio Cascini; Antonio Avallone; Paolo Delrio; Cesare Guida; Fabiana Tatangelo; Pietro Marone; Luigi Aloj; Francesco De Martinis; Pasquale Comella; Valerio Parisi; Secondo Lastoria
Journal:  J Nucl Med       Date:  2006-08       Impact factor: 10.057

5.  Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings.

Authors:  Marco H M Janssen; Michel C Ollers; Ruud G P M van Stiphout; Jeroen Buijsen; Jørgen van den Bogaard; Dirk de Ruysscher; Philippe Lambin; Guido Lammering
Journal:  Radiother Oncol       Date:  2010-01-29       Impact factor: 6.280

6.  Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI.

Authors:  Ken Herrmann; Ralph A Bundschuh; Robert Rosenberg; Stefan Schmidt; Christine Praus; Michael Souvatzoglou; Karen Becker; Tibor Schuster; Markus Essler; Hinrich A Wieder; Helmut Friess; Sibylle I Ziegler; Markus Schwaiger; Bernd J Krause
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

7.  Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging.

Authors:  Ying-Shi Sun; Xiao-Peng Zhang; Lei Tang; Jia-Fu Ji; Jin Gu; Yong Cai; Xiao-Yan Zhang
Journal:  Radiology       Date:  2009-12-17       Impact factor: 11.105

8.  The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT.

Authors:  Robert Rosenberg; Ken Herrmann; Ralf Gertler; Beat Künzli; Markus Essler; Florian Lordick; Karen Becker; Tibor Schuster; Hans Geinitz; Matthias Maak; Markus Schwaiger; Jörg-Rüdiger Siewert; Bernd Krause
Journal:  Int J Colorectal Dis       Date:  2008-12-03       Impact factor: 2.571

9.  Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET.

Authors:  Carlo Capirci; Domenico Rubello; Franca Chierichetti; Giorgio Crepaldi; Angelo Carpi; Andrea Nicolini; Giovanni Mandoliti; Cesare Polico
Journal:  Biomed Pharmacother       Date:  2004-10       Impact factor: 6.529

10.  Locally advanced rectal cancer: diffusion-weighted MR tumour volumetry and the apparent diffusion coefficient for evaluating complete remission after preoperative chemoradiation therapy.

Authors:  Hong Il Ha; Ah Young Kim; Chang Sik Yu; Seong Ho Park; Hyun Kwon Ha
Journal:  Eur Radiol       Date:  2013-06-28       Impact factor: 5.315

View more
  13 in total

Review 1.  Adaptive radiation dose escalation in rectal adenocarcinoma: a review.

Authors:  Jonathan D Van Wickle; Eric S Paulson; Jerome C Landry; Beth A Erickson; William A Hall
Journal:  J Gastrointest Oncol       Date:  2017-10

2.  PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.

Authors:  Oke Gerke; Karen Ehlers; Edith Motschall; Poul Flemming Høilund-Carlsen; Werner Vach
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

3.  Studying local tumour heterogeneity on MRI and FDG-PET/CT to predict response to neoadjuvant chemoradiotherapy in rectal cancer.

Authors:  Niels W Schurink; Simon R van Kranen; Maaike Berbee; Wouter van Elmpt; Frans C H Bakers; Sander Roberti; Joost J M van Griethuysen; Lisa A Min; Max J Lahaye; Monique Maas; Geerard L Beets; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2021-02-10       Impact factor: 5.315

Review 4.  Diffusion-weighted imaging in rectal cancer: current applications and future perspectives.

Authors:  Niels W Schurink; Doenja M J Lambregts; Regina G H Beets-Tan
Journal:  Br J Radiol       Date:  2019-03-05       Impact factor: 3.039

5.  Diffusion-weighted MRI and 18F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model: timeline validation.

Authors:  Yi-Hsiu Chung; Ching-Fang Yu; Shao-Chieh Chiu; Han Chiu; Shin-Ting Hsu; Ching-Rong Wu; Chung-Lin Yang; Ji-Hong Hong; Tzu-Chen Yen; Fang-Hsin Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-24       Impact factor: 9.236

6.  How PET/MR Can Add Value For Children With Cancer.

Authors:  Heike Daldrup-Link
Journal:  Curr Radiol Rep       Date:  2017-02-21

7.  Pretreatment Apparent Diffusion Coefficient Cannot Predict Histopathological Features and Response to Neoadjuvant Radiochemotherapy in Rectal Cancer: A Meta-Analysis.

Authors:  Alexey Surov; Maciej Pech; Maciej Powerski; Katja Woidacki; Andreas Wienke
Journal:  Dig Dis       Date:  2021-03-04       Impact factor: 2.404

8.  Intravoxel incoherent motion diffusion-weighted imaging for discriminating the pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  Wen Lu; Hou Jing; Zhou Ju-Mei; Nie Shao-Lin; Cao Fang; Yu Xiao-Ping; Lu Qiang; Zeng Biao; Zhu Su-Yu; Hu Ying
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

9.  Positron emission tomography-magnetic resonance imaging (PET-MRI) for response assessment after radiation therapy of cervical carcinoma: a pilot study.

Authors:  J E Mongula; F C H Bakers; S Vöö; L Lutgens; T van Gorp; R F P M Kruitwagen; B F M Slangen
Journal:  EJNMMI Res       Date:  2018-01-02       Impact factor: 3.138

10.  Magnetic Resonance Imaging Evaluation in Neoadjuvant Therapy of Locally Advanced Rectal Cancer: A Systematic Review.

Authors:  Roberta Fusco; Mario Petrillo; Vincenza Granata; Salvatore Filice; Mario Sansone; Orlando Catalano; Antonella Petrillo
Journal:  Radiol Oncol       Date:  2017-08-16       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.